PharmaMar signs a commercialization and distribution license agreement for Aplidin® (plitidepsin) with

Megapharm in Israel

Madrid, January 2nd, 2018 - PharmaMar (MSE:PHM) has announced today a commercialization and distribution license agreement with Megapharm Ltd. for the marine-derived anticancer drug Aplidin® (plitidepsin) in Israel and the territory known as the Palestinian Authority.

According to the agreement Megapharm will register Aplidin® on behalf of PharmaMar and distribute the compound in both regions. PharmaMar will retain exclusive production rights and will supply the finished product for clinical and commercial use.

Aplidin® is PharmaMar´s second most advanced anticancer drug which is currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma. The Company announced in March 2016 that plitidepsin has shown positive results in a pivotal Phase III clinical trial (ADMYRE) for multiple myelomai.

According to Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit, "we are about to address our first strategic alliance with Megapharm for the commercialization of Aplidin® for multiple myeloma in Israel and the territory known as the Palestinian Authority. Our commitment is to bring a novel and first-in-class therapy to patients in need."

Miron Drucker, CEO of Megapharm, stated that "the agreement between PharmaMar and Megapharm offers a major advance for healthcare in our territory as Aplidin® provides a novel mechanism of action for treating multiple myeloma; we hope to bring access to the most innovative treatments to our patients in Israel and the territory known as the Palestinian Authority".

About Megapharm Ltd.

Megapharm Ltd. is a leading Israeli private pharma marketing company, founded in 1989, exclusively representing a number of major American, European and Japanese pharmaceutical companies. Megapharm provides its partners with a full set of commercial capabilities, including registration, market access and sales and marketing. Megapharm has demonstrated dynamic sales growth by developing a strong company presence and expertise in selected therapeutic areas (i.e. Oncology, Hematology, CNS,

Orphan and metabolic drugs) and a proven track record for obtaining national reimbursement and inclusion of its products in Health Funds in Israel. Additional information can be found at:www.megapharm.co.il

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, lurbinectedin, plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us atwww.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company.

Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:

Alfonso Ortín - Communications Directoraortin@pharmamar.com Mobile: + 34609493127

Paula Fernández - Media Relations Managerpfalarcon@pharmamar.com Mobile: +34 638796215 Phone: +34 918466000

Investor Relations:

Phone: +34 914444500

Or please visit our website atwww.pharmamar.com

ihttps://www.pharmamar.com/2016/03/31/aplidin-shows-positive-results-in-pivotal-phase-iii-clinical-trial-for-multiple-myeloma/

Pharma Mar SA published this content on 02 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 02 January 2018 08:24:05 UTC.

Original documenthttps://www.pharmamar.com/2018/01/02/pharmamar-signs-a-commercialization-and-distribution-license-agreement-for-aplidin-plitidepsin-with-megapharm-in-israel/

Public permalinkhttp://www.publicnow.com/view/5C23A4ECCC893BBCA13A087D0CA61ADBD970A045